- Home
- SNTG vs APRE Comparison
SNTG vs APRE Comparison
Compare SNTG & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$0.68
Company Overview
Basic Information| Metric | SNTG | APRE |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 6.3M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SNTG | APRE |
|---|---|---|
| Price | $2.17 | $0.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 21.3K | ★ 6.0M |
| Earning Date | 12-19-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $107,507.00 | ★ $488,239.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.43 | $0.55 |
| 52 Week High | $12.70 | $4.65 |
Technical Indicators
Market Signals| Indicator | SNTG | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 46.28 | 37.04 |
| Support Level | $2.22 | $0.55 |
| Resistance Level | $2.45 | $1.49 |
| Average True Range (ATR) | 0.15 | 0.15 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 40.00 | 14.01 |
Price Performance
Historical Comparison SNTG
APRE
About SNTG Sentage Holdings Inc.
Sentage Holdings Inc is a financial service provider that offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.
About APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.